A Study of IBI363 in Subjects with Advanced Solid Malignancies

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(9 sites)

United States

University of California, San Francisco (UCSF), San Francisco, California

Ocala Oncology Center, Ocala, Florida

BRCR Medical Center, Plantation, Florida

University of Kansas Medical Center (KUMC), Fairway, Kansas

Michigan Hematology & Oncology Consultants - MedOnc Dearborn, Dearborn, Michigan